Trial Profile
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Haemorrhage; Telangiectasis
- Focus Therapeutic Use
- Acronyms BABH Study
- 30 Nov 2023 Primary endpoint has not been met. (number of red blood cell transfusions), as per Results published in the Journal of Internal Medicine
- 30 Nov 2023 Results published in the Journal of Internal Medicine
- 18 Jun 2020 Status changed from active, no longer recruiting to completed.